FAK ligand-Linker Conjugate 1 is primarily utilized in the field of targeted cancer therapy. It plays a crucial role in inhibiting focal adhesion kinase (FAK), a protein that is often overexpressed in various cancers and contributes to tumor growth, metastasis, and resistance to treatment. By specifically targeting FAK, this conjugate helps disrupt cancer cell signaling pathways, leading to reduced tumor proliferation and enhanced sensitivity to chemotherapy. Additionally, it is used in research to study the mechanisms of FAK in cancer biology and to develop more effective therapeutic strategies. Its linker component allows for precise delivery and controlled release of the active ligand, improving the efficacy and reducing off-target effects in cancer treatment.